Beta-Methyl Carbapenem Compounds for Gram-Negative Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new antimicrobial agents effective against drug-resistant and multi-drug-resistant gram-negative bacterial infections, as existing carbapenem compounds face challenges such as chemical instability and resistance issues.
Innovation Solution
Development of novel β-methyl carbapenem compounds and their pharmaceutical compositions, including salts and prodrugs, designed to effectively treat gram-negative bacterial infections, with specific structural modifications to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing carbapenem compounds are used to treat gram-negative bacterial infections, then antibacterial activity is achieved, but chemical instability and antibiotic resistance occur
Solution Approach 1:
The patent modifies the chemical structure of carbapenem compounds by introducing a β-methyl group at position 1 of the carbapenem ring and varying substituents at positions 2 and 6. These structural parameter changes enhance chemical stability while preserving antibacterial activity against gram-negative bacteria including resistant strains.
Solution Approach 2:
The invention creates composite molecular structures by combining the carbapenem core with specific side chains (e.g., hydroxyethylthio, carboxymethyl groups) and a β-methyl substituent. This composite approach yields compounds with improved stability profiles and enhanced activity against resistant gram-negative pathogens.
2Reliability
If existing carbapenem compounds are used to treat gram-negative bacterial infections, then antibacterial activity is achieved, but antibiotic resistance develops
Solution Approach 1:
The patent employs systematic variation of substituent parameters at positions 2 and 6 of the carbapenem ring, combined with the β-methyl modification, to create compounds with altered binding characteristics that overcome resistance mechanisms in gram-negative bacteria including ESBL-producing and carbapenem-resistant strains.
Solution Approach 2:
The invention inverts the conventional carbapenem structure by adding a methyl group at the β-position (position 1), which is unconventional for carbapenems. This structural inversion prevents recognition by beta-lactamase enzymes and confers resistance to degradation by resistant bacterial strains.
3Adaptability or versatility
If conventional carbapenem structures are used, then broad spectrum activity is achieved, but chemical instability limits therapeutic use
Solution Approach 1:
The patent introduces a β-methyl group at position 1 and modifies substituents at positions 2 and 6 to achieve optimal balance between broad-spectrum antibacterial activity and chemical stability. Specific substituent combinations (e.g., hydroxyethylthio at position 2, carboxymethyl at position 6) provide both stability and spectrum coverage.
Solution Approach 2:
The patent develops compounds with improved metabolic stability that maintain therapeutic effectiveness without requiring combination therapy with stability-enhancing agents, simplifying the treatment regimen while maintaining broad spectrum coverage.
Data Source
AI summary
The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.